The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Joe Pantene - HC Wainwright. - Analyst
: Hey guys, good afternoon. Thanks for taking the questions. A couple if you don't mind. So first, Matt, with regard to attrition rates, obviously this
is a normal part of biotech drug development. Just curious, I might assume that a lot of it, or the majority has to do with, clinical development
moves, number one, but are there any attrition numbers that might be due to technical issues?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 18, 2025 / 8:30PM, OABI.OQ - Q4 2024 OmniAb Inc Earnings Call
Question: Joe Pantene - HC Wainwright. - Analyst
: No, that's very helpful, and I assume that. I just wanted to ask. And then in your prepared comments and in your slide deck, you gave a little bit of
a tease of new tech rollouts this year. So curious, any further information you can share and does it come from any of your existing platforms or
these sort of brand new rollouts of tech?
Question: Joe Pantene - HC Wainwright. - Analyst
: No, it certainly does. And one more quick question, I guess, and it might be a little self-deprecating. The simplistic answer is a yes, no, or irrelevant.
Do you think that in these current, volatile markets that Kurt alluded to and we all know about, do you think there's any sort of push for additional
pipeline and development where you might see added cash deployment from partners?
Question: Joe Pantene - HC Wainwright. - Analyst
: Fantastic, thanks for indulging all my questions, guys.
Question: Matt Hewitt - Craig Hallam Capital Group - Analyst
: Good afternoon. Thanks for taking the questions. Maybe first up, and I just want to make sure I was reading the slides correctly. So I think you're
expecting 5 to 7 new clinical entrants this year. I would assume that most, if not all, of those would trigger milestones. And then one of the slides
says you've got 4 that are now in phase 3 as we look out, and I'm not asking for guidance, but as we look out at 26, 27. It would appear that she, I
mean, as those kind of get through the clinic, there's an opportunity to see a nice step up in not only the milestones upon approval if that happens,
but also in royalties. Am am I thinking about that correctly?
Question: Matt Hewitt - Craig Hallam Capital Group - Analyst
: It does.
And then maybe shifting gears a little bit. It sounds like you've had some really positive feedback on Omnihab. I know last quarter you said that
you had completed a kind of a beta run or a beta test with with a partner, and then you're going to present data in December. Are you now enrolling
or signing up customers or partners to that product? And if so, how should we think about the ramp of that over the over the year?
Thank you.
Question: Matt Hewitt - Craig Hallam Capital Group - Analyst
: That's great thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 18, 2025 / 8:30PM, OABI.OQ - Q4 2024 OmniAb Inc Earnings Call
Question: Creepa Devarakonda - Thruway Securities - Analyst
: Hey guys, thank you so much for taking my questions and congrats on all the progress.
So on the two licenses with I think Insight and portinia that you reported in Q4, could you give us any additional color either on the therapeutic
areas, the indications, or the platforms that they might use? And from a therapeutic area perspective, you previously have noted that Omni, opens
up a lot more possibilities, especially you mentioned neuroscience as well as oncology. Can you talk about if the trend is continuing or if it has
expanded or or there have been any kind of changes in that?
Thank you.
Question: Creepa Devarakonda - Thruway Securities - Analyst
: Great, thank you.
Question: Stephen Willey - Stifel, Nicolaus & Company, Incorporated - Analyst
: Hi guys, this is Julian for Steve, and thank you for taking the question. So, just to start with, I have a question on your preclinical discovery program.
So among these 5 incremental or in total 20 preclinical programs, is there any particular platform that overrepresents the others? In other words,
like I'm trying to gauge, like.
Any particular platform that's attracting more attention from partners.
So that's my first question and I'll ask the second one later.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 18, 2025 / 8:30PM, OABI.OQ - Q4 2024 OmniAb Inc Earnings Call
Question: Stephen Willey - Stifel, Nicolaus & Company, Incorporated - Analyst
: Okay, great, thank you very much. That's helpful. And my second question is actually related to one of the like advanced assets, so Sugar Mainab
partnering with the Keystone. So, can you please remind me of the downstream economics related to That asset because Keystone sounds like
they've been making, significant progress on the commercial side. So I'm the reason I'm asking this question is I'm wondering if, potential royalty
payment is actually embedded in 2025 guidance revenue guidance at all so.
Question: Stephen Willey - Stifel, Nicolaus & Company, Incorporated - Analyst
: Great, thank you so.
|
